Friday, November 05, 2021 – 06:45am
PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021
As the world’s second largest medical market, ...
The “Summit on COVID-19 Diagnostics & Treatment”
September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing.
The outbreak of Corona Virus Disease 2019 (...
Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid.
Share Article
On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...
Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models
This forum focuses on the interdisciplinary and cutting-edge technologies...
Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...